Perrigo Company plc (PRGO - Free Report) announced that it has received final approval from the FDA for its AB rated generic version of AbbVie Inc.'s (ABBV - Free Report) Androgel Topical Gel. The drug is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Annual market sales for Androgel Topical Gel, 1.62% packets for the 12 months ending May 2017 were about $88 million.
Shares of Perrigo have significantly underperformed the Zacks classified Medical Products industry so far this year. The stock has declined 12.8% against the broader industry’s gain of 21.3%.
Simultaneously, Perrigo also declared that its subsidiary has filed a Paragraph IV Abbreviated New Drug Application (ANDA) with the FDA for a generic version of Galderma’s Soolantra (ivermectin) cream, 1% indicated for the treatment of inflammatory lesions of rosacea. Soolantra’s annual market sales for the 12 months ending May 2017 were $87 million.
However, on the same date, Perrigo settled the litigation related to Meda Pharmaceuticals Inc. and Cipla Ltd’s generic version of Dymista (azelastine hydrochloride and fluticasone propionate) nasal spray. Dymista is indicated for the relief of symptoms of seasonal allergic rhinitis in patients between six years of age and older, who require treatment with both azelastine hydrochloride and fluticasone propionate for symptomatic relief.
The approval for the generic version of a drug bodes well for the company as it will help in boosting revenues. The ANDA once approved will also lead to increased revenues.
Meanwhile, the company has been constantly making acquisitions to expand its business and drive growth. In fact, we are impressed by Perrigo’s growth-by-acquisition strategy. Perrigo has also undertaken certain restructuring initiatives that are expected to support the bottom line, going forward.
Zacks Rank & Stocks to Consider
Perrigo currently carries a Zacks Rank #3 (Hold). Better-ranked health care stocks in the same space include Enzo Biochem, Inc. (ENZ - Free Report) and Sanofi (SNY - Free Report) . While Enzo Biochem sports a Zacks Rank #1 (Strong Buy), Sanofi holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Enzo Biochem’s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 60 days. The company delivered positive earnings surprises in each of the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 68.1% year to date.
Sanofi’s earnings per share estimates increased from $3.08 to $3.18 for 2017 and from $3.26 to $3.30 for 2018, over last 60 days. The company came up with positive earnings surprises in three of the trailing four quarters, with an average beat of 5.10%. The share price of the company has increased 18.9% year to date.
5 Trades Could Profit "Big-League" from Trump Policies If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course. Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Perrigo Company plc (PRGO - Free Report) announced that it has received final approval from the FDA for its AB rated generic version of AbbVie Inc.'s (ABBV - Free Report) Androgel Topical Gel. The drug is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Annual market sales for Androgel Topical Gel, 1.62% packets for the 12 months ending May 2017 were about $88 million.
Shares of Perrigo have significantly underperformed the Zacks classified Medical Products industry so far this year. The stock has declined 12.8% against the broader industry’s gain of 21.3%.
Simultaneously, Perrigo also declared that its subsidiary has filed a Paragraph IV Abbreviated New Drug Application (ANDA) with the FDA for a generic version of Galderma’s Soolantra (ivermectin) cream, 1% indicated for the treatment of inflammatory lesions of rosacea. Soolantra’s annual market sales for the 12 months ending May 2017 were $87 million.
However, on the same date, Perrigo settled the litigation related to Meda Pharmaceuticals Inc. and Cipla Ltd’s generic version of Dymista (azelastine hydrochloride and fluticasone propionate) nasal spray. Dymista is indicated for the relief of symptoms of seasonal allergic rhinitis in patients between six years of age and older, who require treatment with both azelastine hydrochloride and fluticasone propionate for symptomatic relief.
The approval for the generic version of a drug bodes well for the company as it will help in boosting revenues. The ANDA once approved will also lead to increased revenues.
Meanwhile, the company has been constantly making acquisitions to expand its business and drive growth. In fact, we are impressed by Perrigo’s growth-by-acquisition strategy. Perrigo has also undertaken certain restructuring initiatives that are expected to support the bottom line, going forward.
Zacks Rank & Stocks to Consider
Perrigo currently carries a Zacks Rank #3 (Hold). Better-ranked health care stocks in the same space include Enzo Biochem, Inc. (ENZ - Free Report) and Sanofi (SNY - Free Report) . While Enzo Biochem sports a Zacks Rank #1 (Strong Buy), Sanofi holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Enzo Biochem’s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 60 days. The company delivered positive earnings surprises in each of the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 68.1% year to date.
Sanofi’s earnings per share estimates increased from $3.08 to $3.18 for 2017 and from $3.26 to $3.30 for 2018, over last 60 days. The company came up with positive earnings surprises in three of the trailing four quarters, with an average beat of 5.10%. The share price of the company has increased 18.9% year to date.
5 Trades Could Profit "Big-League" from Trump Policies If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course. Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on SNY - FREE
Get the latest research report on PRGO - FREE
Get the latest research report on ENZ - FREE
Get the latest research report on ABBV - FREE